Skip to main content

0

Introduction

Aim

Methods

Results

Conclusions

References

PDF poster

Slide deck

Header - Navigation Icon

Podcast

Infographic panel

Podcast

Laurie Snyder discusses the time from symptom onset and from first imaging evidence of fibrosis to diagnosis of IPF based on data from the IPF-PRO Registry.

Header - Navigation Icon

Slide deck

Infographic panel

The IPF-PRO™ Registry is funded by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI) and coordinated by the Duke Clinical Research Institute (DCRI).

NOTICE:

This website is intended for healthcare professionals only. The posters accessed through this page may discuss and/or present information on investigational uses of nintedanib for which effectiveness and safety have not been established. Nintedanib is indicated for (i) treatment for idiopathic pulmonary fibrosis; (ii) treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype; and (iii) slowing the rate of decline of pulmonary function in patients with systemic sclerosis-associated interstitial lung disease.

CANCEL

Modal title

You are navigating away from the website. Are you sure you want to proceed?